NeoTherapeutics Announces Nasdaq Compliance Date

Max · 06-17-2002, 03:49 PM

NeoTherapeutics Announces Nasdaq Compliance Date

6/17/2002 6:30:00 PM
IRVINE, Calif., Jun 17, 2002 /PRNewswire-FirstCall via COMTEX/ -- NeoTherapeutics, Inc. (NEOT) announced today that Nasdaq has notified the Company that it is not in compliance with Nasdaq's minimum bid price per share ($1.00) requirements for continued listing on the Nasdaq National Market.

CBS MARKETWATCH TOP NEWS
Stocks extend early gains
Dow gets biggest gain in over a month
Enron's Lay was paid $103 million before bankruptcy
Investors gobble up McDonald's stock on better outlook

Sign up for FREE e-newsletters

Get the latest news updated 500 times a day by our 70+ reporters.

TRACK THESE TOPICS
My Portfolio Alerts
Company: NeoTherapeutics Inc Add
Create

Edit My Portfolio | Edit Alerts

The Company has until September 10, 2002 to regain compliance with Nasdaq's minimum bid requirement. Under Nasdaq rules, NeoTherapeutics may demonstrate compliance by maintaining a $1.00 minimum closing bid price per share for a minimum of 10 consecutive trading days by that date. If the Company is unable to demonstrate compliance by that date, the Company may appeal a determination that it be delisted from the Nasdaq National Market, or it may decide to file an application to be transferred to the Nasdaq Small Cap Market prior to September 10, 2002. If such an application were filed and accepted, the Company would have another 90 days, or until December 9, 2002, to comply with the minimum bid requirement. In addition to the minimum bid requirement, the Company must maintain compliance with certain other quantitative standards for continued listing. The Company is currently not in compliance with some of these standards.

NeoTherapeutics seeks to create value for stockholders through the in- licensing and commercialization of anti-cancer drugs, the discovery and licensing out of central nervous system (CNS) drugs, and the licensing out of new drug targets discovered through genomics research. The Company's lead oncology drug, satraplatin, is being prepared for a phase 3 study in prostate cancer. Phase 2 studies of Neotrofin(TM) in Parkinson's disease, spinal cord injury and chemotherapy-induced neuropathy are ongoing. Additional anti-cancer drugs are in phase 1 and 2 human clinical trials, and the Company has a rich pipeline of pre-clinical neurological drug candidates. For additional information visit the Company's web site at www.neot.com.
This press release may contain forward-looking statements regarding future events and the future performance of NeoTherapeutics that involve risks and uncertainties that could cause actual results to differ materially. These risks are described in further detail in the Company's reports filed with the Securities and Exchange Commission.

Contacts: MEDIA RELATIONS Jon Siegal Ronald Trahan Associates (RTA) Inc. (508) 647-9782, ext. 15 INVESTOR RELATIONS John McManus NeoTherapeutics Inc. (949) 788-6700, ext. 247 MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X20223255
SOURCE NeoTherapeutics, Inc.

CONTACT: Jon Siegal of Ronald Trahan Associates (RTA) Inc., +1-508-647- 9782, ext. 15; or John McManus NeoTherapeutics Inc., +1-949-788-6700, ext. 247URL: http://www.neot.comhttp://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved

Max · 08-16-2002, 01:48 PM

NeoTherapeutics Announces Additional NASDAQ Compliance Date
IRVINE, Calif., Aug. 16 /PRNewswire-FirstCall/ -- NeoTherapeutics, Inc. (Nasdaq: NEOT - News) announced today that NASDAQ has notified the Company that it is not in compliance with NASDAQ's requirement to maintain a minimum market value of publicly held shares of $5,000,000 for continued listing on the NASDAQ National Market. ADVERTISEMENT

The Company has until November 11, 2002 to regain compliance with NASDAQ's minimum market value requirement. Under NASDAQ rules, NeoTherapeutics may demonstrate compliance by maintaining a minimum market value of publicly held shares of $5,000,000 or greater for a minimum of 10 consecutive trading days by that date. If the Company is unable to demonstrate compliance by that date, the Company may appeal a determination that it be delisted from the NASDAQ National Market, or it may decide to file an application to be transferred to the NASDAQ SmallCap Market prior to November 11, 2002. However, the Company would have to satisfy the continued listing requirements for that market, which include a minimum market value of publicly held shares of $1,000,000. In addition to the minimum market value of publicly held shares requirement, the Company must maintain compliance with certain other quantitative standards for continued listing on the NASDAQ National Market. The Company is currently not in compliance with some of these standards. The Company previously received notice from NASDAQ on June 12, 2002, that it is not in compliance with NASDAQ's minimum bid price per share requirement of $1.00. The Company has yet to regain compliance with that requirement, and has until September 10, 2002 to do so.

NeoTherapeutics seeks to create value for stockholders through the discovery and out-licensing of drugs for central nervous system disorders and the in-licensing and commercialization of anti-cancer drugs. Neotrofin(TM) is in clinical development in Parkinson's disease, spinal cord injury and chemotherapy-induced neuropathy. Satraplatin, the Company's lead oncology drug, is being prepared for a phase 3 study in prostate cancer. Additional anti-cancer drugs are in phase 1 and 2 stages of development for bladder cancer and non-Hodgkin's lymphoma. The Company has a rich pipeline of pre- clinical neurological drug candidates for important human disorders such as attention deficit hyperactivity disorder, schizophrenia, dementia, mild cognitive impairment, anxiety and pain. For additional information visit the Company's web site at www.neot.com.
This press release may contain forward-looking statements regarding future events and the future performance of NeoTherapeutics that involve risks and uncertainties that could cause actual results to differ materially. These risks are described in further detail in the Company's reports filed with the Securities and Exchange Commission.

Contact:
Carol Gruetter
NeoTherapeutics, Inc.
(949) 788-6700, ext. 236

SOURCE: NeoTherapeutics, Inc.

Max · 08-16-2002, 01:50 PM

06-17-2002, 03:49 PM	#1
Max Senior Member Join Date: Jul 2001 Location: Montreal,Province of Quebec, CANADA Posts: 15,036	NeoTherapeutics Announces Nasdaq Compliance Date NeoTherapeutics Announces Nasdaq Compliance Date 6/17/2002 6:30:00 PM IRVINE, Calif., Jun 17, 2002 /PRNewswire-FirstCall via COMTEX/ -- NeoTherapeutics, Inc. (NEOT) announced today that Nasdaq has notified the Company that it is not in compliance with Nasdaq's minimum bid price per share ($1.00) requirements for continued listing on the Nasdaq National Market. CBS MARKETWATCH TOP NEWS Stocks extend early gains Dow gets biggest gain in over a month Enron's Lay was paid $103 million before bankruptcy Investors gobble up McDonald's stock on better outlook Sign up for FREE e-newsletters Get the latest news updated 500 times a day by our 70+ reporters. TRACK THESE TOPICS My Portfolio Alerts Company: NeoTherapeutics Inc Add Create Edit My Portfolio \| Edit Alerts The Company has until September 10, 2002 to regain compliance with Nasdaq's minimum bid requirement. Under Nasdaq rules, NeoTherapeutics may demonstrate compliance by maintaining a $1.00 minimum closing bid price per share for a minimum of 10 consecutive trading days by that date. If the Company is unable to demonstrate compliance by that date, the Company may appeal a determination that it be delisted from the Nasdaq National Market, or it may decide to file an application to be transferred to the Nasdaq Small Cap Market prior to September 10, 2002. If such an application were filed and accepted, the Company would have another 90 days, or until December 9, 2002, to comply with the minimum bid requirement. In addition to the minimum bid requirement, the Company must maintain compliance with certain other quantitative standards for continued listing. The Company is currently not in compliance with some of these standards. NeoTherapeutics seeks to create value for stockholders through the in- licensing and commercialization of anti-cancer drugs, the discovery and licensing out of central nervous system (CNS) drugs, and the licensing out of new drug targets discovered through genomics research. The Company's lead oncology drug, satraplatin, is being prepared for a phase 3 study in prostate cancer. Phase 2 studies of Neotrofin(TM) in Parkinson's disease, spinal cord injury and chemotherapy-induced neuropathy are ongoing. Additional anti-cancer drugs are in phase 1 and 2 human clinical trials, and the Company has a rich pipeline of pre-clinical neurological drug candidates. For additional information visit the Company's web site at www.neot.com. This press release may contain forward-looking statements regarding future events and the future performance of NeoTherapeutics that involve risks and uncertainties that could cause actual results to differ materially. These risks are described in further detail in the Company's reports filed with the Securities and Exchange Commission. Contacts: MEDIA RELATIONS Jon Siegal Ronald Trahan Associates (RTA) Inc. (508) 647-9782, ext. 15 INVESTOR RELATIONS John McManus NeoTherapeutics Inc. (949) 788-6700, ext. 247 MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X20223255 SOURCE NeoTherapeutics, Inc. CONTACT: Jon Siegal of Ronald Trahan Associates (RTA) Inc., +1-508-647- 9782, ext. 15; or John McManus NeoTherapeutics Inc., +1-949-788-6700, ext. 247URL: http://www.neot.comhttp://www.prnewswire.com Copyright (C) 2002 PR Newswire. All rights reserved

08-16-2002, 01:48 PM	#2
Max Senior Member Join Date: Jul 2001 Location: Montreal,Province of Quebec, CANADA Posts: 15,036	NeoTherapeutics Announces Additional NASDAQ Compliance Date NeoTherapeutics Announces Additional NASDAQ Compliance Date IRVINE, Calif., Aug. 16 /PRNewswire-FirstCall/ -- NeoTherapeutics, Inc. (Nasdaq: NEOT - News) announced today that NASDAQ has notified the Company that it is not in compliance with NASDAQ's requirement to maintain a minimum market value of publicly held shares of $5,000,000 for continued listing on the NASDAQ National Market. ADVERTISEMENT The Company has until November 11, 2002 to regain compliance with NASDAQ's minimum market value requirement. Under NASDAQ rules, NeoTherapeutics may demonstrate compliance by maintaining a minimum market value of publicly held shares of $5,000,000 or greater for a minimum of 10 consecutive trading days by that date. If the Company is unable to demonstrate compliance by that date, the Company may appeal a determination that it be delisted from the NASDAQ National Market, or it may decide to file an application to be transferred to the NASDAQ SmallCap Market prior to November 11, 2002. However, the Company would have to satisfy the continued listing requirements for that market, which include a minimum market value of publicly held shares of $1,000,000. In addition to the minimum market value of publicly held shares requirement, the Company must maintain compliance with certain other quantitative standards for continued listing on the NASDAQ National Market. The Company is currently not in compliance with some of these standards. The Company previously received notice from NASDAQ on June 12, 2002, that it is not in compliance with NASDAQ's minimum bid price per share requirement of $1.00. The Company has yet to regain compliance with that requirement, and has until September 10, 2002 to do so. NeoTherapeutics seeks to create value for stockholders through the discovery and out-licensing of drugs for central nervous system disorders and the in-licensing and commercialization of anti-cancer drugs. Neotrofin(TM) is in clinical development in Parkinson's disease, spinal cord injury and chemotherapy-induced neuropathy. Satraplatin, the Company's lead oncology drug, is being prepared for a phase 3 study in prostate cancer. Additional anti-cancer drugs are in phase 1 and 2 stages of development for bladder cancer and non-Hodgkin's lymphoma. The Company has a rich pipeline of pre- clinical neurological drug candidates for important human disorders such as attention deficit hyperactivity disorder, schizophrenia, dementia, mild cognitive impairment, anxiety and pain. For additional information visit the Company's web site at www.neot.com. This press release may contain forward-looking statements regarding future events and the future performance of NeoTherapeutics that involve risks and uncertainties that could cause actual results to differ materially. These risks are described in further detail in the Company's reports filed with the Securities and Exchange Commission. Contact: Carol Gruetter NeoTherapeutics, Inc. (949) 788-6700, ext. 236 SOURCE: NeoTherapeutics, Inc.

08-16-2002, 01:50 PM	#3
Max Senior Member Join Date: Jul 2001 Location: Montreal,Province of Quebec, CANADA Posts: 15,036	Maybe all of us should buy Neotherapeutics shares :)

Thread Tools
Show Printable Version Email this Page
Display Modes
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode